| |
Placebo (n = 20)
|
TGD 300 mg/day (n = 20)
|
TGD 900 mg/day (n = 20)
|
p value
|
|---|
|
Characteristic
|
|
Sex (male/female)
|
9/11
|
14/6
|
12/8
|
0.272
|
|
Age (year)
|
61.8 ± 8.1
|
62.4 ± 10.3
|
62.7 ± 8.3
|
0.928
|
|
Body mass index (kg/m2)
|
22.8 ± 4.2
|
25.1 ± 4.8
|
23.2 ± 3.1
|
0.187
|
|
HbA1c (%)
|
6.9 ± 0.7
|
6.7 ± 0.5
|
6.7 ± 0.4
|
0.319
|
|
Fasting blood glucose (mg/dL)
|
141.4 ± 35.3
|
143.8 ± 20.1
|
148.8 ± 23.7
|
0.677
|
|
Insulin (mU/mL)
|
9.2 ± 8.1
|
13.7 ± 17.5
|
13.2 ± 21.9
|
0.651
|
|
Nutrients
|
|
Energy (Kcal)
|
1565 ± 320
|
1768 ± 417
|
1671 ± 321
|
0.203
|
|
Protein (g)
|
51.3 ± 11.1
|
56.9 ± 11.7
|
52.7 ± 8.4
|
0.203
|
|
Fat (g)
|
39.8 ± 7.3
|
45.0 ± 10.3
|
39.3 ± 8.2
|
0.069
|
|
Cholesterol (mg)
|
254 ± 80
|
234 ± 53
|
235 ± 64
|
0.548
|
|
Ongoing diabetes therapies, n (%)
|
|
Insulin injection
|
3 (15)
|
2 (10)
|
6 (30)
|
0.235
|
|
Metoformin
|
5 (25)
|
7 (35)
|
5 (25)
|
0.720
|
|
Insulin secretagogue
|
13 (65)
|
12 (60)
|
9 (45)
|
0.414
|
|
α-Glicosidase inhibitor
|
8 (40)
|
10 (50)
|
10 (50)
|
0.765
|
|
PPAR-γ antagonist
|
5 (25)
|
5 (25)
|
5 (25)
|
1.000
|
|
≥2 diabetes drugs
|
11 (55)
|
11 (55)
|
9 (45)
|
0.766
|
|
Lifestyle modification only
|
2 (4)
|
1 (5)
|
2 (4)
|
0.804
|
- TGD, transglucosidase; HbA1c, glycolated hemoglobin.
